Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery

Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery is a phase 3, randomised interventional study registered as NCT07632118 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 288 participants, started 2026-05-22 and due to reach its primary completion in 2029-05. Interventions recorded: Radiotherapy + GX; GX group. Conditions listed: Pancreatic Cancer. Primary outcome: DFS. Pancreatic eligibility wording from the registry: "* Confirmed as pancreatic ductal adenocarcinoma by histopathology or cytology, with no evidence of distant metastasis confirmed by imaging". Sites: China. No results are recorded here; the registry entry is the source.